Oslo, 7 October 2025: Reference is made to the stock exchange announcement
published by Navamedic ASA (the "Company") earlier today regarding the final
result of the rights issue in the Company (the "Rights Issue").
Kistefos AS has today been allocated a total of 4,811,758 new shares in the
Rights Issue.
In addition, Kistefos AS will receive 255,813 new shares in the Company (the
"Underwriting Commission Shares") as settlement for having underwritten an
amount of NOK 110 million in the Rights Issue. The underwriting fee amounts to 5
per cent of the underwritten amount and is paid in new shares in the Company.
Following completion of the Rights Issue and the issuance of the Underwriting
Commission Shares, Kistefos AS (6 413 195 shares) and its sister company
Kistefos Investment AS, which are both controlled by Christen Sveaas, will hold
a total of 7,413,195 shares in the Company, representing 30.91% of the
outstanding shares and votes in the Company following registration of the new
shares in the Norwegian Register of Business Enterprises. Accordingly, Kistefos
AS will have exceeded the 25% disclosure threshold and Kistefos AS and Kistefos
Investment AS will jointly have exceeded the 30% disclosure threshold.
The new shares will be set in forward share contracts (nw:
"terminfinansiering").
This information is subject to the disclosure requirements set out in section
4-2 of the Norwegian Securities Trading Act.